|
시장보고서
상품코드
2109016
자가면역질환 치료제 : 시장 동향, 경쟁 구도 및 시장 예측(2034년)Autoimmune Disease Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2034 |
||||||
DelveInsight
개요:
- 자가면역질환 치료제 시장은 2025년에 132억 7,500만 달러로 추산되며, 2034년까지 254억 6,000만 달러에 달할 것으로 예측됩니다. 이러한 성장은 전 세계 자가면역질환 유병률 증가, 생물학적 제제 및 표적 지향형 경구 치료제의 급속한 확대, 그리고 세포 치료 및 유전자 치료와 같은 다양한 치료 방식을 아우르는 면역학 파이프라인에 대한 지속적인 제약 투자가 뒷받침하고 있습니다.
- 전 세계 자가면역 질환 치료제 시장은 2026년부터 2034년까지의 예측 기간 동안 연평균 성장률(CAGR) 7.5%로 성장하고 있습니다.
- 치료제 유형별로는 2025년에 생물학적 제제 부문이 66%의 점유율을 차지하며 자가면역 질환 치료제 시장을 주도했습니다.
- 약제 유형별로는 2025년에 종양괴사인자(TNF) 억제제 부문이 29%의 점유율을 차지하며 자가면역 질환 치료제 시장을 주도했습니다.
- 투여 경로별로는 2025년에 피하 투여 부문이 자가면역 질환 치료제 시장에서 54%의 점유율을 차지하며 시장을 주도했습니다.
- 질환별로는 2025년에 류마티스 관절염(RA) 부문이 자가면역 질환 치료제 시장에서 34%의 점유율을 차지하며 시장을 주도했습니다.
- 2025년, 북미는 전 세계 자가면역질환 치료제 시장 매출에서 44%의 점유율을 차지하며, 전 세계적으로 가장 높은 지역별 시장 점유율을 기록했습니다.
자가면역질환 치료제란, 면역계가 실수로 자신의 조직을 공격하는 질환(류마티스 관절염, 건선성 관절염, 다발성 경화증, 전신성 홍반성 루푸스, 건선, 염증성 장질환 등)의 관리에 사용되는 의약품 및 생물학적 제제를 말합니다. 이러한 질환은 만성적이고 재발성이며, 완치되는 경우가 극히 드물기 때문에 치료는 완치보다는 장기적인 면역 조절에 중점을 두고 있으며, 제약 기업들은 광범위하게 작용하는 면역억제제에서 작용기전이 특이적인 생물학적 제제나 경구용 저분자 의약품으로 점차 전환하고 있습니다. 본 시장은 약물 모달리티별로 저분자 의약품, 생물학적 제제, 세포 치료, 유전자 치료, 기타로 분류됩니다. 약제 분류별로는 TNF 억제제가 주도적이며, 인터루킨(IL) 억제제, B세포 억제제, 야누스 키나제(JAK) 억제제가 시장을 빠르게 확대되고 있습니다. 투여 경로별로는 경구, 정맥 내, 피하 투여가 있으며, 질환 유형별로는 류마티스 관절염을 필두로 건선성 관절염, 다발성 경화증, 전신성 홍반성 루푸스, 기타 적응증이 포함됩니다. 진단율 상승, JAK 및 IL 계열 약물의 적응증 확대 추세, 그리고 난치성 자가면역질환에 대한 CAR-T 및 기타 세포 치료법의 등장 등에 힘입어, 자가면역질환 치료제 시장은 전 세계 면역학 및 전문 의약품 산업의 핵심을 이루고 있습니다.
자가면역 질환 치료제 시장의 주요 성장 요인
- 전 세계적으로 자가면역 질환의 유병률이 높아짐에 따라 치료 대상이 되는 환자층이 확대되고 있습니다. 80개 이상의 알려진 질환에 걸쳐, 자가면역 질환은 전 세계 인구의 약 5-9%에 영향을 미치는 것으로 추정됩니다.
- 생물학적 제제 및 표적 지향형 경구 요법의 임상적·상업적 확장이 지속되면서 수요를 견인하고 있습니다. 애브비(AbbVie)의 'Skyrizi'와 'Rinvoq'는 2025년 면역학 분야에서 총 매출 300억 달러 이상을 창출할 것으로 예상되며, 두 약제 모두 백반증 및 원형 탈모증에 대한 새로운 승인 신청이 진행 중입니다.
- JAK, IL-17 및 IL-23 억제제 계열의 적응증 확대와 신규 승인이 가속화되고 있으며, 화이자(Pfizer)사의 ‘Litfulo’가 중증 원형 탈모증에 대해 승인된 것을 포함해 대상 환자층이 확대되고 있습니다.
- 로슈, 노바티스 및 신흥 바이오테크 기업들의 프로그램을 필두로, 전신성 홍반성 루푸스 및 다발성 경화증을 대상으로 한 B세포 제거 요법 및 CAR-T 세포 요법의 파이프라인 활동이 활발해지고 있어, 난치성 질환에 대한 새로운 치료법이 개척되고 있습니다.
- 아달리무맙 등 기존 TNF 억제제를 둘러싼 바이오시밀러 간 경쟁이 격화됨에 따라, 환자의 접근성과 가격을 중시한 도입이 확대되는 한편, 원개발 제약사의 전략은 보다 새로운 작용기전으로 전환되고 있습니다.
- 헬스케어 분야의 의료비 증가, 진단 능력 향상, 그리고 환자 인식 제고에 힘입어 진단까지 걸리는 기간이 단축되고, 조기 단계에서의 치료 시작이 증가하고 있습니다.
- 생물학적 제제의 혁신, 적응증 확대, 바이오시밀러의 보급, 그리고 새로운 세포 및 유전자 치료법의 등장이 맞물려, 2034년까지 시장은 안정적인 한 자릿수 대의 성장을 유지할 것으로 예측됩니다.
자가면역질환 치료제 시장의 성장에 기여하는 요인
시장 성장 촉진요인
세계 자가면역질환 유병률 상승
자가면역질환 치료제 시장의 가장 근본적인 촉진요인은 전 세계적으로 꾸준히 증가하고 있는 자가면역질환의 유병률입니다. 80유형 이상의 다양한 자가면역 질환이 알려져 있으며, 이를 합산하면 전 세계 인구의 약 5-9%가 이 질환을 앓고 있는 것으로 추정됩니다. 또한, 특정 자가면역 질환을 앓고 있는 환자의 약 4분의 1은 이후 다른 자가면역 질환을 발병하게 됩니다. 류마티스 관절염, 건선성 관절염, 다발성 경화증, 전신성 홍반성 루푸스가 여전히 가장 많은 환자가 진단받는 질환이지만, 유전적 소인, 환경적 유발 요인 및 진단 인식의 향상으로 인해 특정 환자층은 계속해서 확대되고 있습니다. 진단율 향상과 치료를 추구하는 행동 증가에 따라, 생물학적 제제 및 표적 지향형 경구 요법의 대상 환자층도 마찬가지로 확대되고 있으며, 이는 예측 기간 동안 지속적인 장기 수요를 뒷받침하는 기반이 되고 있습니다.
생물학적 제제 및 표적 지향형 경구 치료제의 급속한 확대
작용기전에 특화된 생물학적 제제 및 경구 저분자 약물의 임상적·상업적 부상은 시장의 주요 성장 동력이 되고 있습니다. 인터루킨 억제제 및 야누스 키나제 억제제는 2차 선택 약물에서 조기 치료 적용으로 빠르게 전환되고 있으며, 그 상업적 성과는 눈부십니다. 애브비(AbbVie)의 ‘스카이라지(Skyrizi)’와 ‘린복(Rinvoq)’은 2026년 총 매출이 300억 달러를 넘어설 것으로 예상되며, 기존 ‘휴미라(Humira)’에 대한 바이오시밀러로 인한 매출 감소를 상쇄할 것으로 전망됩니다. 이러한 약물은 기존의 면역억제제보다 면역 경로를 더 정밀하게 표적화하기 때문에 내약성 향상과 치료 효과의 지속성으로 이어지고 있습니다. 파이프라인이 성숙해지고 새로운 작용기전을 가진 약물이 상업적 규모에 도달함에 따라, 류마티스학, 피부과, 소화기내과, 신경내과 등 각 적응증 분야에서 첨단 바이오의약품 및 표적 지향형 경구 치료제에 대한 수요는 지속적으로 확대되고 있습니다.
시장 제약 요인
강력한 성장세를 보이고 있음에도 불구하고, 자가면역질환 치료제 시장은 중대한 제약에 직면해 있습니다. 생물학적 제제나 표적 지향형 경구 치료제는 환자 1인당 연간 수만 달러를 초과하는 경우도 드물지 않을 정도로 고비용이 들기 때문에 특히 가격에 민감한 시장이나 신흥 시장에서 보험 적용 및 접근성과 관련된 큰 장벽이 되고 있습니다. 바이오시밀러 및 제네릭 의약품과의 경쟁이 격화되면서 접근성은 확대되는 반면, 오리지널 의약품의 가격과 매출은 압박을 받고 있습니다.
자가면역 질환은 만성적이고 재발을 반복하는 특성을 가지고 있기 때문에 이용 가능한 치료법의 대부분은 근본적인 질환을 완치시키는 것이 아니라 증상 관리나 진행 지연을 목적으로 합니다. 또한, 작용기전에 따라 환자의 반응이 다르기 때문에 치료법 선택이 복잡해지고 있습니다. JAK 억제제의 박스 경고 등 특정 약물 군과 관련된 안전성 우려로 인해, 일부 환자 집단에서는 보다 신중한 처방이 이루어지고 있습니다. 새로운 작용기전, 특히 세포 및 유전자 치료와 관련된 장기간에 걸친 복잡한 규제 절차로 인해 개발 기간이 연장되고 비용이 증가하고 있습니다. 한편, 전신성 홍반성 루푸스 등 복잡한 질환의 진단 지연으로 인해 치료 시작이 계속 늦어지고 있습니다. 이러한 비용, 경쟁, 안전성, 진단과 관련된 장벽들이 복합적으로 작용함에 따라, 유병률 상승, 생물학적 제제의 혁신, 치료 접근성 확대와 같은 근본적인 성장 요인들이 여전히 견조하게 유지되고 있음에도 불구하고 성장 속도는 둔화되고 있습니다.
자주 묻는 질문
목차
제1장 자가면역질환 치료제 시장 : 서론
제2장 자가면역질환 치료제 시장 : 주요 요약
제3장 자가면역질환 치료제 시장 : 주요 요인 분석
제4장 AI, 지정학, 무역 및 경제 동향
제5장 규제 분석
제6장 Porter의 Five Forces 분석
제7장 자가면역질환 치료제 시장 : 평가
제8장 자가면역질환 치료제 시장 : 경쟁 구도
제9장 자가면역질환 치료제 시장 : 스타트업의 자금조달 및 투자 동향
제10장 자가면역질환 치료제 시장 : 기업 개요 및 제품 개요
제11장 KOL(Key Opinion Leader)의 견해
제12장 프로젝트 접근
제13장 DelveInsight에 대해
제14장 면책사항 및 문의
LSH 26.08.13Autoimmune Disease Therapeutics Market Summary
Overview:
- The Autoimmune Disease Therapeutics market is estimated at USD 132.75 billion in 2025 and is projected to reach USD 254.60 billion by 2034. Growth is anchored in the rising global prevalence of autoimmune disorders, the rapid expansion of biologic and targeted oral therapies, and sustained pharmaceutical investment in immunology pipelines spanning cell- and gene-based modalities.
- The global Autoimmune Disease Therapeutics market is growing at a CAGR of 7.5% during the forecast period from 2026 to 2034.
- By drug modality, the biologics segment dominated the Autoimmune Disease Therapeutics market with a 66% share in 2025.
- By drug class, the Tumor Necrosis Factor (TNF) Inhibitors segment dominated the Autoimmune Disease Therapeutics market with a 29% share in 2025.
- By route of administration, the subcutaneous segment dominated the Autoimmune Disease Therapeutics market with a 54% share in 2025.
- By disease type, the Rheumatoid Arthritis (RA) segment dominated the Autoimmune Disease Therapeutics market with a 34% share in 2025.
- North America dominated the global Autoimmune Disease Therapeutics market revenue with a 44% share in 2025, representing the highest regional market share globally.
Autoimmune disease therapeutics comprise the drugs and biologic agents used to manage conditions in which the immune system mistakenly attacks the body's own tissues, including rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus, psoriasis, and inflammatory bowel disease. Because these disorders are chronic, relapsing, and only rarely curable, treatment is centered on long-term immune modulation rather than cure, and sponsors have progressively shifted from broad immunosuppressants toward mechanism-specific biologics and oral small molecules. The market is organized by drug modality across small molecules, biologics, cell-based therapies, gene-based therapies, and others; by drug class, led by TNF inhibitors alongside a fast-growing base of interleukin (IL) inhibitors, B-cell inhibitors, and Janus kinase (JAK) inhibitors; by route of administration spanning oral, intravenous, and subcutaneous delivery; and by disease type, led by rheumatoid arthritis alongside psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus, and other indications. Driven by rising diagnosis rates, an expanding wave of label expansions for JAK and IL-class agents, and the emergence of CAR-T and other cell-based approaches for refractory autoimmune disease, the Autoimmune Disease Therapeutics market has become a core pillar of the global immunology and specialty pharmaceutical industry.
Autoimmune Disease Therapeutics Market Key Growth Drivers
- The rising global prevalence of autoimmune disorders is expanding the treated patient pool, with autoimmune diseases collectively affecting an estimated 5-9% of the world's population across more than 80 recognized conditions.
- Continued clinical and commercial expansion of biologic and targeted oral therapies is driving demand, with AbbVie's Skyrizi and Rinvoq together generating more than USD 30 billion in combined 2025 immunology revenue and both drugs receiving new regulatory submissions in vitiligo and alopecia areata.
- Accelerating label expansions and new approvals across JAK, IL-17, and IL-23 inhibitor classes, including Pfizer's Litfulo approval for severe alopecia areata, are broadening addressable patient populations.
- Growing pipeline activity in B-cell-depleting and CAR-T cell-based therapies for systemic lupus erythematosus and multiple sclerosis, led by programs from Roche, Novartis, and emerging biotech innovators, is opening new modalities of care for refractory disease.
- Intensifying biosimilar competition for legacy TNF inhibitors such as adalimumab is expanding patient access and price-based adoption while shifting originator strategy toward newer mechanisms.
- Rising healthcare expenditure, improved diagnostic capability, and growing patient awareness are shortening diagnosis timelines and increasing early-stage treatment initiation.
- The convergence of biologic innovation, label expansion, biosimilar penetration, and emerging cell- and gene-based modalities is expected to sustain steady, high-single-digit growth in the market through 2034.
Key Companies in Autoimmune Disease Therapeutics Market
The competitive landscape is led by the following active manufacturers:
- AbbVie
- Johnson & Johnson
- Pfizer
- Novartis
- Roche
- Amgen
- Eli Lilly and Company
- Bristol Myers Squibb
- UCB
- Sanofi
Factors Contributing to the Growth of the Autoimmune Disease Therapeutics Market
Market Drivers
Rising Global Prevalence of Autoimmune Disorders
The most fundamental driver of the Autoimmune Disease Therapeutics market is the steadily rising global prevalence of autoimmune disease. More than 80 distinct autoimmune conditions are recognized, collectively affecting an estimated 5-9% of the world's population, and roughly a quarter of patients with one autoimmune disorder go on to develop a second. Rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, and systemic lupus erythematosus remain the largest diagnosed populations, while genetic predisposition, environmental triggers, and improved diagnostic awareness continue to expand the identified patient base. As diagnosis rates improve and treatment-seeking behavior increases, the addressable population for biologic and targeted oral therapies grows in step, anchoring durable long-term demand across the forecast period.
Rapid Expansion of Biologic and Targeted Oral Therapies
The clinical and commercial rise of mechanism-specific biologics and oral small molecules is a central growth engine for the market. Interleukin inhibitors and Janus kinase inhibitors have moved rapidly from second-line to earlier use, and commercial performance is substantial: AbbVie's Skyrizi and Rinvoq together are expected to generate more than USD 30 billion in combined 2026 revenue, offsetting continued biosimilar erosion of legacy Humira. These agents deliver more precise immune-pathway targeting than older immunosuppressants, translating into better tolerability and durability of response. As pipelines mature and new mechanisms reach commercial scale, demand for advanced biologic and targeted oral treatment continues to expand across rheumatology, dermatology, gastroenterology, and neurology indications.
Market Restraints
Despite strong momentum, the Autoimmune Disease Therapeutics market faces material constraints. The high cost of biologic and targeted oral therapies, often exceeding tens of thousands of dollars annually per patient, creates significant reimbursement and access barriers, particularly in price-sensitive and emerging markets. Intensifying biosimilar and generic competition compresses originator pricing and revenue even as it expands access.
The chronic, relapsing nature of autoimmune disease means most available treatments manage symptoms and slow progression rather than cure the underlying condition, and heterogeneous patient response across mechanisms complicates treatment selection. Safety concerns associated with certain drug classes, including boxed warnings for JAK inhibitors, have prompted more conservative prescribing in some patient populations. Lengthy and complex regulatory pathways for novel mechanisms, particularly cell- and gene-based therapies, extend development timelines and raise costs, while diagnostic delays for complex conditions such as systemic lupus erythematosus continue to defer treatment initiation. Together, these cost, competitive, safety, and diagnostic barriers temper the pace of growth, even as the underlying drivers of rising prevalence, biologic innovation, and expanding treatment access remain firmly intact.
Autoimmune Disease Therapeutics Market Segment Analysis
The autoimmune disease therapeutics market by drug modality (small molecules, biologics, cell-based therapies, gene-based therapies, and others), drug class (tumor necrosis factor (tnf) inhibitors, interleukin (il) inhibitors, b-cell inhibitors, janus kinase (jak) inhibitors, and others), route of administration (oral, intravenous (iv), subcutaneous, and others), disease type (rheumatoid arthritis (ra), psoriatic arthritis (psa), multiple sclerosis (ms), systemic lupus erythematosus (sle), and others), end-users (hospitals, specialty clinics, and others), and geography (North America, Europe, Asia-Pacific, and Rest of World).
By Drug Modality
Dominant Subsegment: Biologics.
The biologics segment accounted for 66% of the Autoimmune Disease Therapeutics market in 2025. Biologics are the leading drug modality because monoclonal antibodies and fusion proteins deliver precise, mechanism-specific immune modulation with a well-established efficacy and safety record across rheumatoid arthritis, psoriasis, psoriatic arthritis, and inflammatory bowel disease. Franchise biologics such as AbbVie's Skyrizi, Johnson & Johnson's Tremfya, and Novartis' Cosentyx continue to post double-digit growth as they capture share from older mechanisms and expand into new indications. The breadth of approved biologic classes, spanning TNF, IL-17, IL-23, and BAFF inhibitors, combined with an accelerating biosimilar pipeline that broadens access to lower-cost biologic treatment, sustains the segment's scale. While cell-based and gene-based therapies represent the fastest-growing modalities as CAR-T and B-cell-depleting approaches advance in lupus and multiple sclerosis, the depth of the approved biologic portfolio and its central role in first-line and second-line treatment secure the segment's leadership across the forecast period.
By Drug Class
Dominant Subsegment: TNF Inhibitors.
The TNF inhibitors segment accounted for 29% of the Autoimmune Disease Therapeutics market in 2025. TNF inhibitors remain the leading drug class because agents such as adalimumab, etanercept, infliximab, and UCB's Cimzia carry decades of clinical validation across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease, and continue to anchor first-line biologic treatment in many markets. The expanding availability of adalimumab biosimilars is broadening access and sustaining high treatment volumes even as originator revenue erodes. At the same time, IL inhibitors are the fastest-growing drug class, propelled by IL-17 and IL-23 agents such as Cosentyx, Tremfya, Skyrizi, and UCB's Bimzelx, while JAK inhibitors, led by Rinvoq and Pfizer's Litfulo, are expanding rapidly into new indications including alopecia areata and vitiligo, and B-cell inhibitors such as GSK's Benlysta anchor systemic lupus erythematosus treatment. Nonetheless, the breadth of approved indications and the sheer prescription volume of TNF inhibitors secure the class's leadership across the forecast period.
Autoimmune Disease Therapeutics Market Region Analysis
Dominant Region: North America
North America accounted for 44% of the global Autoimmune Disease Therapeutics market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a mature immunology treatment ecosystem, deep clinical-research infrastructure, broad payer coverage of biologics, and clear FDA regulatory pathways, particularly in the United States. North America hosts the largest concentration of biologic and targeted oral therapy prescribing and the deepest late-stage immunology pipeline, and sponsors benefit from proximity to leading immunology developers including AbbVie, Johnson & Johnson, Amgen, and Bristol Myers Squibb. The commercial success of franchises such as Skyrizi, Rinvoq, Tremfya, and Cosentyx, combined with rapid uptake of newly approved indications and a deep clinical pipeline in lupus and multiple sclerosis, drives substantial treatment demand. Strong reimbursement, regulatory clarity, and the concentration of major immunology manufacturers anchor the region's continued leadership across the forecast period.
Fastest Growing Region: Asia-Pacific
Asia-Pacific is the fastest-growing region in the Autoimmune Disease Therapeutics market. The region's elevated CAGR is driven by rising autoimmune disease diagnosis rates, expanding healthcare infrastructure, and growing biologic adoption across China, Japan, India, South Korea, and Australia. China is rapidly expanding access to biologics and advancing domestic CAR-T approvals for systemic lupus erythematosus, Japan continues to broaden reimbursement for advanced immunology therapies, and India benefits from growing biosimilar manufacturing capacity and increasing specialist access. Rising healthcare investment, expanding insurance coverage, and growing patient and physician awareness are accelerating adoption, while regional manufacturers scale biosimilar production and pursue global regulatory alignment. The combination of a large undertreated patient population, healthcare infrastructure build-out, and biosimilar manufacturing growth positions Asia-Pacific as the principal source of incremental growth over the forecast period.
Regional Commentary
North America
North America accounted for 44% of the global Autoimmune Disease Therapeutics market revenue in 2025. The United States dominates on the strength of its immunology treatment infrastructure, deep clinical-research base, FDA regulatory clarity, and broad payer coverage of biologic therapies, while the commercial strength of Skyrizi, Rinvoq, Tremfya, and Cosentyx, alongside an active late-stage pipeline in lupus and multiple sclerosis, reinforces the region's leadership.
Europe
Europe is a large and advanced regional market, supported by established EMA regulatory frameworks, strong national health systems, and a deep base of immunology manufacturers including UCB, Sanofi, Novartis, and Roche. Growing biosimilar adoption, expanding reimbursement for IL-17 and IL-23 inhibitors, and active clinical development in multiple sclerosis and lupus reinforce the region's role in both innovator and biosimilar autoimmune therapeutics across Germany, France, the United Kingdom, Italy, and Spain.
Asia-Pacific
Asia-Pacific is the fastest-growing region, propelled by rising autoimmune disease diagnoses, expanding healthcare infrastructure, and growing biologic and biosimilar adoption across China, Japan, India, South Korea, and Australia. China's advancing CAR-T approvals for lupus, Japan's broadening biologic reimbursement, India's biosimilar manufacturing growth, and rising specialist access across the region are accelerating adoption and clinical-trial activity.
Rest of World
The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding healthcare infrastructure, rising diagnosis of autoimmune disorders, and growing access to biosimilar therapies are gradually broadening treatment access, while international partnerships and local manufacturing investment support the build-out of regional biologic and biosimilar supply.
Autoimmune Disease Therapeutics Market Competitive Landscape
The Autoimmune Disease Therapeutics market is classified as Moderately Concentrated. A group of large, diversified immunology leaders with deep biologic and targeted oral portfolios, including AbbVie, Johnson & Johnson, Novartis, and Roche, secures large prescribing shares and anchors the top tier, while specialized and fast-scaling players such as UCB, Amgen, Sanofi, GSK, Biogen, Takeda, and Merck KGaA compete through mechanism differentiation, indication expansion, and dedicated cell- and gene-based therapy pipelines, increasing competition in the fastest-growing disease segments.
The competitive landscape can be evaluated across the following dimensions:
- Market concentration: Moderately concentrated, with large diversified immunology leaders anchoring the top tier and a growing field of specialized biologic and cell-therapy developers.
- Leading players: AbbVie, Johnson & Johnson, Novartis, and Roche anchor the top tier through breadth of approved biologic and oral portfolios and deep late-stage pipelines.
- Geographic reach: Leaders operate global commercial networks spanning North America, Europe, and Asia-Pacific, supported by regional manufacturing and biosimilar production capacity.
- Portfolio strength: Top players offer multi-mechanism portfolios spanning TNF, IL-17, IL-23, JAK, and B-cell-targeted agents across rheumatology, dermatology, gastroenterology, and neurology.
- Pipeline depth: Late-stage programs in cell-based and gene-based therapies for systemic lupus erythematosus and multiple sclerosis, alongside next-generation oral and biologic candidates, are a decisive advantage.
- Label expansion strategy: Continuous indication expansion, such as AbbVie's Rinvoq submissions in vitiligo and alopecia areata and Roche's Gazyva submission in lupus, extends commercial reach for existing molecules.
- M&A and licensing activity: Active licensing and pipeline in-licensing, alongside continued investment in emerging cell-therapy platforms, is expanding manufacturer access to next-generation mechanisms.
- Commercial capabilities: Deep specialist-physician relationships, patient-support programs, and autoinjector and self-administration technology are key competitive differentiators.
- Innovation focus: Cell-based and gene-based therapy scale-up, next-generation oral small molecules, biosimilar portfolio expansion, and precision biomarker-driven treatment selection.
Autoimmune Disease Therapeutics Market Recent Developmental Activities
In 2026, AbbVie raised its full-year revenue outlook for Skyrizi and Rinvoq to approximately USD 21.6 billion and USD 10.2 billion, respectively, and submitted regulatory applications for Rinvoq in vitiligo and alopecia areata. Strategic significance: Reinforces AbbVie's position as the leading immunology franchise and extends its addressable dermatology-autoimmune population.
In April 2026, Roche submitted a supplemental Biologics License Application for Gazyva (obinutuzumab) to expand its use into systemic lupus erythematosus, with an FDA decision expected in December 2026. Strategic significance: Repurposes an established immuno-oncology biologic to strengthen Roche's lupus and B-cell-depletion portfolio.
Autoimmune Disease Therapeutics Market Segmentation
Autoimmune Disease Therapeutics Market by Drug Modality
- Small Molecules
- Biologics
- Cell-Based Therapies
- Gene-Based Therapies
- Others
Autoimmune Disease Therapeutics Market by Drug Class
- Tumor Necrosis Factor (TNF) Inhibitors
- Interleukin (IL) Inhibitors
- B-cell Inhibitors
- Janus Kinase (JAK) Inhibitors
- Others
Autoimmune Disease Therapeutics Market by Route of Administration
- Oral
- Intravenous (IV)
- Subcutaneous
- Others
Autoimmune Disease Therapeutics Market by Disease Type
- Rheumatoid Arthritis (RA)
- Psoriatic Arthritis (PsA)
- Multiple Sclerosis (MS)
- Systemic Lupus Erythematosus (SLE)
- Others
Autoimmune Disease Therapeutics Market by End-Users
- Hospitals
- Specialty Clinics
- Others
Autoimmune Disease Therapeutics Market by Geography
- North America Autoimmune Disease Therapeutics Market
- United States Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- Canada Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- Mexico Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- Europe Autoimmune Disease Therapeutics Market
- Germany Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- United Kingdom Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- France Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- Italy Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- Spain Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- Rest of Europe Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- Asia-Pacific Autoimmune Disease Therapeutics Market
- China Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- Japan Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- India Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- Australia Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- South Korea Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- Rest of Asia-Pacific Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- Rest of the World (RoW) Autoimmune Disease Therapeutics Market
- Middle East Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- Africa Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- South America Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
Key Takeaways from the Autoimmune Disease Therapeutics Market Report Study
- Market size analysis for the current autoimmune disease therapeutics market size (2025), and market forecast for 9 years (2026 to 2034).
- Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
- Key companies dominating the global autoimmune disease therapeutics market.
- Various opportunities available for competitors in the autoimmune disease therapeutics market space.
- What are the top-performing segments in 2025? How will these segments perform in 2034?
- Which are the top-performing regions and countries in the current autoimmune disease therapeutics market scenario?
- Which are the regions and countries where companies should concentrate their opportunities for autoimmune disease therapeutics market growth in the future?
Target audience who can benefit from this Autoimmune Disease Therapeutics market report study
- Autoimmune disease therapeutics product providers
- Research organizations and consulting companies
- Neurodegenerative disease therapeutics-related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and traders dealing in autoimmune disease therapeutics
- Various end-users who want to know more about the autoimmune disease therapeutics market and the latest technological developments in the autoimmune disease therapeutics market.
Frequently Asked Questions:
Q1. What is the growth rate of the autoimmune disease therapeutics market?
The autoimmune disease therapeutics market is projected to expand at a CAGR of 7.5% during the forecast period from 2026-2034.
Q2. What is the market size of the autoimmune disease therapeutics market?
The autoimmune disease therapeutics market is estimated at USD 254.60 billion in 2025 and is projected to reach SD 271.30 billion by 2034.
Q3. Which region dominates the autoimmune disease therapeutics market?
North America dominated the Autoimmune Disease Therapeutics market with a 44% share of global revenue in 2025, supported by a mature immunology treatment ecosystem, deep clinical-research infrastructure, broad payer coverage of biologics, FDA regulatory clarity, and the largest concentration of leading immunology manufacturers. Asia-Pacific is the fastest-growing region over the forecast period.
Q4. What are the key drivers of the autoimmune disease therapeutics market?
The principal drivers are the rising global prevalence of autoimmune disorders, affecting an estimated 5-9% of the world's population; the rapid clinical and commercial expansion of biologic and targeted oral therapies, with AbbVie's Skyrizi and Rinvoq generating more than USD 30 billion in combined 2026 revenue; accelerating regulatory approvals and label expansions; the emergence of cell-based and gene-based therapies for refractory disease; and intensifying biosimilar competition that is broadening treatment access.
Q5. Who are the major players in the autoimmune disease therapeutics market?
The major players include AbbVie, Johnson & Johnson, Pfizer, Novartis, Roche, Amgen, Eli Lilly and Company, Bristol Myers Squibb, UCB, Sanofi, GSK, Biogen, Takeda, and Merck KGaA, among other active providers profiled in the Competitive Landscape section. AbbVie, Johnson & Johnson, Novartis, and Roche lead through breadth of approved biologic and targeted oral portfolios and deep late-stage pipelines.
Table of Contents
1. Autoimmune Disease Therapeutics Market Report Introduction
- 1.1 Scope of the Study
- 1.2 Market Segmentation
- 1.3 Market Assumptions
2. Autoimmune Disease Therapeutics Market Executive Summary
- 2.1 Market at a Glance
3. Autoimmune Disease Therapeutics Market Key Factors Analysis
- 3.1 Autoimmune Disease Therapeutics Market Drivers
- 3.1.1 Rising Global Prevalence of Autoimmune Disorders
- 3.1.2 Expansion of Biologic and Targeted Oral Therapies
- 3.1.3 Accelerating Regulatory Approvals and Label Expansions
- 3.1.4 Emergence of Cell-Based and Gene-Based Therapies
- 3.2 Autoimmune Disease Therapeutics Market Restraints and Challenges
- 3.2.1 High Cost of Biologic and Targeted Oral Therapies
- 3.2.2 Biosimilar and Generic Competitive Pressure
- 3.2.3 Safety, Diagnostic, and Regulatory Complexity
- 3.3 Autoimmune Disease Therapeutics Market Opportunities
- 3.3.1 Cell-Based and Gene-Based Therapy Scale-Up
- 3.3.2 Emerging-Market and Biosimilar Access Expansion
4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
5. Regulatory Analysis
- 5.1 United States
- 5.2 Europe
- 5.3 Japan
- 5.4 China
6. Autoimmune Disease Therapeutics Market Porter's Five Forces Analysis
- 6.1 Bargaining Power of Suppliers
- 6.2 Bargaining Power of Buyers
- 6.3 Threat of New Entrants
- 6.4 Threat of Substitutes
- 6.5 Competitive Rivalry
7. Autoimmune Disease Therapeutics Market Assessment
- 7.1 By Drug Modality
- 7.1.1 Small Molecules
- 7.1.2 Biologics
- 7.1.3 Cell-Based Therapies
- 7.1.4 Gene-Based Therapies
- 7.1.5 Others
- 7.2 By Drug Class
- 7.2.1 Tumor Necrosis Factor (TNF) Inhibitors
- 7.2.2 Interleukin (IL) Inhibitors
- 7.2.3 B-cell Inhibitors
- 7.2.4 Janus Kinase (JAK) Inhibitors
- 7.2.5 Others
- 7.3 By Route of Administration
- 7.3.1 Oral
- 7.3.2 Intravenous (IV)
- 7.3.3 Subcutaneous
- 7.3.4 Others
- 7.4 By Disease Type
- 7.4.1 Rheumatoid Arthritis (RA)
- 7.4.2 Psoriatic Arthritis (PsA)
- 7.4.3 Multiple Sclerosis (MS)
- 7.4.4 Systemic Lupus Erythematosus (SLE)
- 7.4.5 Others
- 7.5 By End-Users
- 7.5.1 Hospitals
- 7.5.2 Specialty Clinics
- 7.5.3 Others
- 7.6 By Geography
- 7.6.1 North America
- 7.6.1.1 United States Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- 7.6.1.2 Canada Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- 7.6.1.3 Mexico Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- 7.6.2 Europe
- 7.6.2.1 Germany Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- 7.6.2.2 United Kingdom Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- 7.6.2.3 France Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- 7.6.2.4 Italy Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- 7.6.2.5 Spain Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- 7.6.2.6 Rest of Europe Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- 7.6.3 Asia-Pacific
- 7.6.3.1 China Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- 7.6.3.2 Japan Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- 7.6.3.3 India Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- 7.6.3.4 Australia Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- 7.6.3.5 South Korea Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- 7.6.3.6 Rest of Asia-Pacific Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- 7.6.4 Rest of World
- 7.6.4.1 Middle East Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- 7.6.4.2 Africa Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- 7.6.4.3 South America Autoimmune Disease Therapeutics Market Size in USD million (2023-2034)
- 7.6.1 North America
8. Autoimmune Disease Therapeutics Market Competitive Landscape
- 8.1 Market Concentration and Structure
- 8.2 Competitive Positioning and Market Share Analysis (Premium Offering)
9. Autoimmune Disease Therapeutics Market Startup Funding and Investment Trends
10. Autoimmune Disease Therapeutics Market Company and Product Profiles
- 10.1 AbbVie Inc.
- 10.1.1 Company Overview
- 10.1.2 Company Snapshot
- 10.1.3 Financial Overview
- 10.1.4 Service Portfolio
- 10.1.5 Strategic Initiatives / Entropy
- 10.2 Johnson & Johnson
- 10.2.1 Company Overview
- 10.2.2 Company Snapshot
- 10.2.3 Financial Overview
- 10.2.4 Product Portfolio
- 10.2.5 Strategic Initiatives / Entropy
- 10.3 Novartis AG
- 10.3.1 Company Overview
- 10.3.2 Company Snapshot
- 10.3.3 Financial Overview
- 10.3.4 Product Portfolio
- 10.3.5 Strategic Initiatives / Entropy
- 10.4 F. Hoffmann-La Roche Ltd
- 10.4.1 Company Overview
- 10.4.2 Company Snapshot
- 10.4.3 Financial Overview
- 10.4.4 Product Portfolio
- 10.4.5 Strategic Initiatives / Entropy
- 10.5 Sanofi
- 10.5.1 Company Overview
- 10.5.2 Company Snapshot
- 10.5.3 Financial Overview
- 10.5.4 Product Portfolio
- 10.5.5 Strategic Initiatives / Entropy
- 10.6 Amgen Inc.
- 10.6.1 Company Overview
- 10.6.2 Company Snapshot
- 10.6.3 Financial Overview
- 10.6.4 Product Portfolio
- 10.6.5 Strategic Initiatives / Entropy
- 10.7 UCB S.A.
- 10.7.1 Company Overview
- 10.7.2 Company Snapshot
- 10.7.3 Financial Overview
- 10.7.4 Product Portfolio
- 10.7.5 Strategic Initiatives / Entropy
- 10.8 Pfizer
- 10.8.1 Company Overview
- 10.8.2 Company Snapshot
- 10.8.3 Financial Overview
- 10.8.4 Product Portfolio
- 10.8.5 Strategic Initiatives / Entropy
- 10.9 GSK plc
- 10.9.1 Company Overview
- 10.9.2 Company Snapshot
- 10.9.3 Financial Overview
- 10.9.4 Product Portfolio
- 10.9.5 Strategic Initiatives / Entropy
- 10.10 Eli Lilly and Company
- 10.10.1 Company Overview
- 10.10.2 Company Snapshot
- 10.10.3 Financial Overview
- 10.10.4 Product Portfolio
- 10.10.5 Strategic Initiatives / Entropy
For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.
